关于 Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
总部251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
成立2018
状态营业中
专利1 项专利
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
法律信息
| 法定名称 | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20在 GLEIF 上查看 ↗ |
| 注册地址 | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| 状态 | 营业中 |
来源: GLEIF · 更新于 Oct. 16, 2026
联系方式和链接
地点
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
这是你的公司吗?
免费认领此页面,即可添加标志、产品、照片和职位,并回复评价。
认领此页面